Contextualizing single‐arm trials with real‐world data: An emulated target trial comparing therapies for neovascular age‐related macular degeneration
Authors:
- Adnan TufailATAdnan Tufail
- UK AMD EMR Users GroupUGUK AMD EMR Users Group
Open Access
- 9 January 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 14 (3) , 1166-1175
Abstract
One‐in‐four ophthalmology trials are single‐armed, which poses challenges to their interpretation. We demonstrate how real‐world cohorts used as external/synthetic control arms can contextualise such trials. We herein emulated a target trial on the intention‐to‐treat efficacy of off‐label bevacizumab (q6w) pro re nata relative to fixed‐interval aflibercept (q8w) for improving week‐54 visual acuity of eyes affected by neovascular age‐related macular degeneration. The bevacizumab arm (n 65) was taken from the ABC randomised controlled trial. A total of 4,471 aflibercept‐treated eyes aligning with the ABC trial eligibility were identified from Electronic Health Records and synthetic control arms were created by emulating randomisation conditional on age, sex, and baseline visual read via exact matching and propensity score methods. We undertook an inferiority analysis on mean difference at 54 weeks; outcomes regression on achieving a change in visual acuity of ≥ 15, ≥ 10, and ≤ ‐15 Early Treatment Diabetic Retinopathy (ETDRS) letters at week 54; and a time‐to‐event analysis on achieving a change in visual acuity of ≥ 15, ≥ 10, and ≤ ‐15 ETDRS letters by week 54. The findings suggest off‐label bevacizumab to be neither non‐inferior nor superior to licensed aflibercept. Our study highlights how real‐world cohorts representing the counterfactual intervention could aid the interpretation of single‐armed trials when analysed in accord to the target trial framework.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018American Journal of Ophthalmology, 2020
- Beyond Randomized Clinical Trials: Use of External ControlsClinical Pharmacology & Therapeutics, 2019
- Avoidable flaws in observational analyses: an application to statins and cancerNature Medicine, 2019
- Nonrandomized Real‐World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication ProjectClinical Pharmacology & Therapeutics, 2019
- Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled TrialsClinical Pharmacology & Therapeutics, 2019
- Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With ApplesAmerican Journal of Epidemiology, 2019
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016
- Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaBlood Cancer Journal, 2016
- Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External ControlsJournal of Thoracic Oncology, 2016
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016